Nebraska Center for Nanomedicine- Bioimaging Core

内布拉斯加州纳米医学中心 - 生物成像核心

• 批准号: 10163873
• 负责人: Yutong Liu
• 金额: $ 28.21万
• 依托单位: UNIVERSITY OF NEBRASKA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10163873
• 关键词: Address; Adhesions; Anatomy; Animals; Antibodies; Binding; Biochemical; Biodistribution; Bioinformatics; Biological Markers; Biology; Blood Vessels; Blood flow; Brain; Cancer Center; Cardiac; Cardiovascular Diseases; Cells; Cellular biology; Centers of Research Excellence; Chronic; Collaborations; Communities; Computer software; Contrast Media; Core Facility; Custom; Data; Databases; Detection; Development; Developmental Biology; Disease; Drug Delivery Systems; Dyes; Equipment; Evaluation; Expenditure; Fees; Fertilization; Frequencies; Funding; Goals; Grant; Hemoglobin; Human; Hypoxia; Image; Imaging Device; Immunology; Individual; Institution; Label; Lasers; Letters; Link; Magnetic Resonance Imaging; Methodology; Methods; Microscope; Molecular Probes; Monitor; Nano delivery; Nebraska; Neoplasms in Vascular Tissue; Neurobiology; Operating System; Optics; Organ; Output; Oxygen; Pathway interactions; Perfusion; Phase; Physiological; Physiology; Pre-Clinical Model; Process; Proteins; Research; Research Personnel; Resolution; Rodent; Rodent Model; Scheme; Services; Sonication; Statistical Data Interpretation; Stress; Structure; System; Technology; Tissues; Training; Tumor Biology; Ultrasonography; Visual; Visualization; Work; angiogenesis; animal imaging; base; bioimaging; cancer imaging; cell motility; clinical application; data warehouse; efficacy evaluation; experience; experimental study; fluorophore; heart function; hemodynamics; image processing; imaging facilities; imaging modality; imaging system; in vivo; insight; instrument; instrumentation; intravital microscopy; longitudinal animal study; nanomaterials; nanomedicine; nanoparticle; novel therapeutics; organizational structure; photoacoustic imaging; pre-clinical; quantitative imaging; response; senior faculty; tool; tumor; tumor growth

ABSTRACT Bioimaging is an essential research tool. The ability for high fidelity anatomical localization of proteins and nanodelivery agents is an indispensable component in the development of new therapeutics. Furthermore, new imaging modalities allow for a highly sensitive way of binding structure to function with high resolution in small animals. As such, we will utilize a single Core structure to house three instruments that will be utilized by investigators associated with this COBRE. Small animal magnetic resonance imaging (MRI) will be available using two preclinical 7 Tesla MRI scanners, one Bruker Biospec 7T/21cm MRI/MRS system operating Avance III hardware and one Bruker Pharmascan system (7T/16 cm). High frequency ultrasound (up to 40 MHz) alone and combined with photoacoustic laser imaging will use the Visual Sonics 2100 and 3100 instruments equipped with the LAZR-X technology. Finally, a new state-of-the-art intravital microscopy system includes an Olympus FVMPE-RS multiphoton laser confocal microscope with 2 line lasers. The bioimaging core will be directed by three experienced senior faculty who have been associated with this COBRE for many years. The Core directors will oversee the function of each piece of instrumentation and direct technical staff. In association with Core they will monitor expenditures and recommend adjustments in user fees as necessary. Importantly, the Bioimaging Core will provide essential training to the investigators for specific uses. Given the capabilities of these instruments, it is anticipated that a wide variety of studies will take place related to nanomedicine. This includes nanoparticle biodistribution, cell tracking, hemoglobin saturation, blood flow, antibody adhesion, cardiac and vascular function, angiogenesis and live vascular and tumor imaging. Based on current grant support we estimate a continuously active Core that will grow in use. The Core will be actively engaged in the development of new imaging tools and unique ways of advancing investigators' research. A key component in the administration of this Core is insuring its sustainability beyond Phase III. Outstanding institutional support combined with adjustment of user fees will provide long-term funding. RELEVANCE Non-invasive evaluation using clinically applicable imaging methods is a critical step in the translational pathway towards human use of nanomedicines. Access to experts in imaging and state-of-the-art equipment will allow for training new investigators in the use of quantitative in-vivo methodologies and the important details to be addressed when planning such experiments.

摘要 生物成像是一种重要的研究工具。蛋白质的高保真解剖定位能力， 纳米递送剂是开发新疗法中不可或缺的组分。此外，新 成像模式允许以高灵敏度的方式结合结构，以在小的、高分辨率的环境中发挥作用。 动物因此，我们将利用一个单一的核心结构来容纳三种工具， 与眼镜蛇有关的调查员小动物磁共振成像（MRI）将可 使用两台临床前7 T MRI扫描仪，一台Bruker Biospec 7 T/21 cm MRI/MRS系统运行Avance III硬件和一个Bruker Pharmascan系统（7 T/16 cm）。单独使用高频超声（高达40 MHz） 结合光声激光成像，将使用Visual Sonics 2100和3100仪器 配备LAZR-X技术。最后，一种新的最先进的活体显微镜系统包括： Olympus FVMPE-RS多光子激光共聚焦显微镜，带2线激光器。生物成像的核心将是 由三位经验丰富的资深教师指导，他们多年来一直与COBRE有关。的 核心主管将监督每件仪器的功能并指导技术人员。在 他们将与核心小组合作，监测支出情况，并在必要时建议调整使用费。 重要的是，生物成像核心将为研究人员提供必要的培训，以用于特定用途。鉴于 这些仪器的能力，预计将进行各种各样的研究， 纳米医学这包括纳米颗粒生物分布，细胞跟踪，血红蛋白饱和度，血流， 抗体粘附、心脏和血管功能、血管生成以及活血管和肿瘤成像。基于 在目前的赠款支持下，我们估计一个持续活跃的核心将在使用中增长。核心将积极 致力于开发新的成像工具和独特的方法来推进研究人员的研究。一个关键 核心项目管理的一个重要组成部分是确保其在第三阶段之后的可持续性。优秀 机构支助加上调整使用费将提供长期资金。 相关性 使用临床适用的成像方法进行非侵入性评估是转化的关键步骤。 人类使用纳米药物的途径。接触成像专家和最先进的设备 将允许培训新的研究人员使用定量体内方法， 在规划此类实验时需要注意的细节。